Adcirca and Agranulocytosis - a phase IV clinical study of FDA data


Agranulocytosis is found among people who take Adcirca, especially for people who are female, 30-39 old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Adcirca and have Agranulocytosis. It is created by eHealthMe based on reports of 51,667 people who have side effects when taking Adcirca from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Nov, 28, 2022

51,667 people reported to have side effects when taking Adcirca.
Among them, 38 people (0.07%) have Agranulocytosis.

What is Adcirca?

Adcirca has active ingredients of tadalafil. It is often used in pulmonary hypertension. eHealthMe is studying from 51,715 Adcirca users for its effectiveness, alternative drugs and more.

What is Agranulocytosis?

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection) is found to be associated with 3,103 drugs and 3,330 conditions by eHealthMe.

Number of Adcirca and Agranulocytosis reports submitted per year:

Could Adcirca cause Agranulocytosis?

Time on Adcirca when people have Agranulocytosis *:

  • < 1 month: 50 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 50 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Agranulocytosis when taking Adcirca *:

  • female: 65.71 %
  • male: 34.29 %

Age of people who have Agranulocytosis when taking Adcirca *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 48 %
  • 40-49: 16 %
  • 50-59: 12 %
  • 60+: 24 %

Common drugs people take besides Adcirca *:

  1. Opsumit: 15 people, 39.47%
  2. Remodulin: 7 people, 18.42%
  3. Letairis: 6 people, 15.79%
  4. Tracleer: 5 people, 13.16%
  5. Isentress: 5 people, 13.16%
  6. Flolan: 5 people, 13.16%
  7. Epivir: 5 people, 13.16%
  8. Viread: 5 people, 13.16%
  9. Slow-K: 5 people, 13.16%
  10. Lasix: 4 people, 10.53%

Common side effects people have besides Agranulocytosis *:

  1. White Blood Cell Count Decreased: 8 people, 21.05%
  2. Anaemia (lack of blood): 8 people, 21.05%
  3. Concomitant Disease Aggravated (advanced due to some of accompanying): 7 people, 18.42%
  4. Alanine Aminotransferase Increased: 5 people, 13.16%
  5. Aspartate Aminotransferase Increased: 5 people, 13.16%
  6. Diarrhea: 5 people, 13.16%
  7. Pneumonia: 5 people, 13.16%
  8. Breathing Difficulty: 4 people, 10.53%
  9. General Physical Health Deterioration (weak health status): 3 people, 7.89%
  10. Hospitalisation: 3 people, 7.89%

Common conditions people have *:

  1. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 28 people, 73.68%
  2. Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 2 people, 5.26%
  3. Hiv Infection: 2 people, 5.26%
  4. Pulmonary Embolism (blockage of the main artery of the lung): 2 people, 5.26%
  5. Infusion Site Pain: 2 people, 5.26%
  6. Hypersensitivity: 2 people, 5.26%
  7. Cardiac Failure: 1 person, 2.63%
  8. Depression: 1 person, 2.63%
  9. Dyslipidaemia (abnormal amount of lipids): 1 person, 2.63%
  10. Essential Hypertension (primary hypertension): 1 person, 2.63%

* Approximation only. Some reports may have incomplete information.

Do you take Adcirca and have Agranulocytosis?

Check whether Agranulocytosis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Related studies

How severe was Agranulocytosis and when was it recovered:

Expand to all the drugs that have ingredients of tadalafil:

Alternative drugs to, pros and cons of Adcirca:

Common Adcirca side effects:

Browse all side effects of Adcirca:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Agranulocytosis treatments and more:

COVID vaccines that are related to Agranulocytosis:

Common drugs associated with Agranulocytosis:

All the drugs that are associated with Agranulocytosis:

Common conditions associated with Agranulocytosis:

All the conditions that are associated with Agranulocytosis:

How the study uses the data?

The study uses data from the FDA. It is based on tadalafil (the active ingredients of Adcirca) and Adcirca (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: